Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof

Patent metadata

Field	Value
Publication number	US-11077187-B2
Application number	US-201615775056-A
Country	US
Kind code	B2
Filing date	Nov 15, 2016
Priority date	Nov 17, 2015
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

First claim

The invention claimed is:

1. A human or humanized monoclonal antibody or human or humanized antibody fragment that is capable of specifically binding activated human protein C, but not unactivated human protein C, wherein said antibody or antibody fragment comprise a variable light chain of SEQ ID NO: 19 but with an N→D substitution at position 85 and a variable heavy chain of SEQ ID NO: 15.

2. The antibody or antibody fragment of claim 1 , wherein the antibody is a diabody or minibody.

3. The antibody or antibody fragment of claim 1 , wherein the antibody is germ-lined, affinity matured or framework shuffled antibody.

4. The antibody or antibody fragment of claim 1 , wherein the antibody is a bispecific antibody or a chimeric antibody.

5. The antibody or antibody fragment of claim 1 , wherein the antibody is a humanized or antibody.

6. The antibody or antibody fragment of claim 1 , wherein said antibody is a single chain antibody.

7. The antibody or antibody fragment of claim 1 , wherein said antibody fragment is an Fab′.

8. The antibody or antibody fragment of claim 1 , wherein said antibody is capable of specifically binding an epitope in the autolysis lysis loop of the human activated protein C.

9. A pharmaceutical composition comprising an antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier or diluent.

10. A method of treating a subject in need of coagulation comprising administering to said subject an human or humanized antibody or human or humanized antibody fragment that is capable of specifically binding activated human protein C, but not unactivated human protein C, wherein said antibody or antibody fragment comprise a variable light chain of SEQ ID NO: 19 but with an N→D substitution at position 85 and a variable heavy chain of SEQ ID NO: 15.

11. The method of claim 10 , wherein the antibody is a diabody or minibody.

12. The method of claim 10 , wherein the antibody is a single chain antibody, a bispecific antibody or a chimeric antibody.

13. The method of claim 10 , wherein the antibody is a humanized antibody.

14. The method of claim 10 , wherein said antibody fragment is an Fab′.

15. The method of claim 10 , wherein said antibody is capable of specifically binding an epitope in the autolysis lysis loop of the human activated protein C.

16. The method of claim 10 , wherein said subject suffers from hemophilia or other bleeding diseases.

17. The method of claim 16 , wherein the disease is including acute bleeding and/or bleeding associated with traumatic coagulopathy (endogenous acute coagulopathy EAC).

Assignees

• Oklahoma Med Res Found

Inventors

• Zhao Xiao-Yan
• Wilmen Andreas
• Freiberg Christoph
• Linden Lars
• Kim Ji-Yun
• Yegneswaran Subramanian
• Regnstrom Karin
• Egner Ursula
• Wang Xinquan

Classifications

• C07K16/40 Primary

  against enzymes · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title